Overview A Study of HBM9161 in NMOSD Patients Status: Active, not recruiting Trial end date: 2021-12-31 Target enrollment: Participant gender: Summary Primary Objectives:To investigate the safety and tolerability of HBM 9161 in patients with attack of NMOSD in China Phase: Phase 1 Details Lead Sponsor: Harbour BioMed (Guangzhou) Co. Ltd.